Why the US Military Is Racing to Build Fake Blood
Blood has a logistics problem. Whole blood lasts 35 days refrigerated, platelets a week or less, and thawed plasma or red cells spoil within days. That fragility costs lives — roughly 90% of preventable battlefield deaths come from hemorrhage, and a JAMA study of combat injuries in Afghanistan points to a 36-minute window for transfusions. DARPA's new $73 million RAPIID program wants to fix that with dried, shelf-stable blood products deployable by 2029.
The 36-Minute Problem
A JAMA study of combat injuries in Afghanistan suggests a magic number: get blood started within 36 minutes, or survival odds drop precipitously. Lieutenant Commander Robert Murray, a Navy officer and DARPA program manager, studied the 2007 loss of a casualty evacuation helicopter called Morphine 1-2 — shot down during a daylight 'blood run' through insurgent territory. That incident crystallized why blood supply lines are a battlefield vulnerability. In the civilian world, a 2025 Transfusion study found that of 1.2 million US trauma patients who potentially needed blood before reaching a hospital, just 1% received it — roughly 10,000 preventable deaths annually, per the American College of Surgeons.
What DARPA Is Actually Funding
RAPIID, a $73 million program, follows the $47.5 million FSHARP effort and targets shelf-stable versions of all three major transfusion components: plasma, platelets, and red blood cells. Murray wants bags of dried blood products in the field by 2029, with trials running in parallel and coordinated with the FDA. The program also has to solve unglamorous problems — combat-durable storage bags, and tests that can tell how much artificial blood a patient already has. Plasma is the closest to done: the FDA has recently allowed two freeze-dried plasma types for emergency military use, and one is cleared for civilians too.
Red Blood Cells Are the Hard Part
Hemoglobin carries oxygen, but it comes wrapped in a cell membrane for good evolutionary reason. 'Naked' hemoglobin breaks down fast, damages organs, and scavenges nitric oxide — constricting blood vessels. That's what sank 1990s-era HBOCs like HemAssist: in one trial, 24 of 52 recipients died versus eight of 46 controls, and a 2008 JAMA review found HBOCs roughly tripled heart attack risk. KaloCyte's ErythroMer takes a different route, packaging upcycled donor hemoglobin inside a lipid nanoparticle that mimics a cell membrane, with a pH-responsive lipid called KC-1003 controlling oxygen uptake and release. It freeze-dries for two-year room-temperature storage and, in a 2016 rodent study, stabilized blood pressure without the vessel constriction that killed HemAssist.
Key Takeaways
- About 90% of preventable battlefield deaths come from hemorrhage, and the transfusion window is roughly 36 minutes.
- DARPA's $73 million RAPIID program aims to field dried, shelf-stable plasma, platelets, and red blood cells by 2029.
- Freeze-dried plasma is already cleared for emergency military use, with one version available to civilians.
- Red blood cells remain the hardest target; past hemoglobin-based carriers failed on safety, and lab-grown blood failed on cost.
Source: MIT Tech Review • 🇺🇸 San Francisco
Keep Reading
